drugset / Trial / NCT01315249
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe COPD.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone | Other / unclassified | 500 ug | Inhaled |
| Subject | Glycopyrronium | Unknown | 50 ug | Inhaled |
| Subject | Indacaterol | Other / unclassified | 110 ug | Inhaled |
| Comparator | Salmeterol | Other / unclassified | 50 ug | Inhaled |